ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

December 29, 2021 GMT

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Dec 29, 2021--

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

ADVERTISEMENT

Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent ®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent injectW device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211229005055/en/

CONTACT: Chris Lewis

Sr. Director, Investor Relations & Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH PHARMACEUTICAL OPTICAL

SOURCE: Glaukos Corporation

Copyright Business Wire 2021.

PUB: 12/29/2021 07:00 AM/DISC: 12/29/2021 07:02 AM

http://www.businesswire.com/news/home/20211229005055/en